Release Date: XXXXX;
Expiration Date: XXXXXX
According to the most recent data in the US Census, nearly 40% of Americans identify as either black, African American, Asian, Hispanic, Latino, Hawaiian, or Pacific Islander – all of which can comprise the population of Americans with skin of color (“United States Census Bureau” 2019). Given that these proportions are projected to increase in the future, it makes sense that clinicians should be knowledgeable about diagnosing and treating medical conditions for patients in this populations (“Skin of Color Society” 2020a). However, there are gaps in dermatologic care today concerning patients with skin of color (SOC) that need to be addressed through education and putting new knowledge into practice.
Patients with SOC can be disproportionately affected by numerous dermatologic conditions. This includes inflammatory skin disorders, forms of skin cancer, pigmentation disorders, and hair loss. Even children with SOC can be more susceptible or have a greater disease burden, especially with skin disorders common in pediatric patients such as scalp conditions and atopic dermatitis. It is important for clinicians to understand the many different ways in which patients with SOC may be affected by these conditions. Certain skin disorders may be more prevalent in patients with SOC, others may be less prevalent but more severe. That severity is worsened by the fact that many existing treatments for these conditions have not been extensively tested in SOC patient populations. In some cases, a disorder is not necessarily more or less prevalent in this patient population, but a lack of training for dermatologists has led to underdiagnosis or misdiagnosis of the condition in patients with darker pigmented skin. In addition, many patients with SOC have historically faced greater barriers to dermatologic care due to racial bias and difference in socioeconomic level (“The Dermatologist” 2012). It is critical that dermatologists are aware of these unique challenges and how to accommodate them when diagnosing and treating SOC patients.
In addition to the considerations needed when diagnosing and treating patients with darker pigmented skin, it is important to also note the systemic issues behind these disparities. There is a lack of training for dermatologists in diagnosis and treatment of hair and skin conditions in patients with SOC, as well as minimal proportions of dermatologist who have darker pigmented skin. Between the gaps in formal training and a lack of clinicians who look similar to their patients, it is imperative that dermatologists receive education that allows them to change their practice to address these disparities. This program is designed to address these gaps in dermatologic care for SOC patients by reviewing skin conditions prevalent in SOC patients or those which disproportionately burden SOC patients. Participants will gain education needed to better treat these conditions and modify current practices to accommodate the needs of patients with darker pigmented skin.
This activity is designed to meet the needs physicians, nurses and professional staff members of medical practices specializing in dermatology.
Upon completion of the educational activity, participants should be able to:
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. If you have any questions relating to the accreditation of this activity, please contact AKH at firstname.lastname@example.org
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 4.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
4.75 ANCC contact hours
This activity is supported by educational grants from Galderma Laboratories, L.P. and Incyte Corporation.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.